IPCA Labs Lowers Margin Guidance, Targets 9–10% Growth in FY26

💊

has revised its FY26 consolidated EBITDA margin guidance to a 75 bps improvement versus the earlier 100 bps target, while projecting 9–10% topline growth. In the US market, the company plans 5–6 annual launches, with 15–16 products in development. The earlier Rs 300 crore EBITDA target for Unichem is unlikely to be met this year, though management expects improvement in coming quarters.